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Psychobiological factors of resilience and
depression in late life
Kelsey T. Laird1, Beatrix Krause1, Cynthia Funes1 and Helen Lavretsky1
Abstract
In contrast to traditional perspectives of resilience as a stable, trait-like characteristic, resilience is now recognized as a
multidimentional, dynamic capacity influenced by life-long interactions between internal and environmental
resources. We review psychosocial and neurobiological factors associated with resilience to late-life depression (LLD).
Recent research has identified both psychosocial characteristics associated with elevated LLD risk (e.g., insecure
attachment, neuroticism) and psychosocial processes that may be useful intervention targets (e.g., self-efficacy, sense
of purpose, coping behaviors, social support). Psychobiological factors include a variety of endocrine, genetic,
inflammatory, metabolic, neural, and cardiovascular processes that bidirectionally interact to affect risk for LLD onset
and course of illness. Several resilience-enhancing intervention modalities show promise for the prevention and
treatment of LLD, including cognitive/psychological or mind–body (positive psychology; psychotherapy; heart rate
variability biofeedback; meditation), movement-based (aerobic exercise; yoga; tai chi), and biological approaches
(pharmacotherapy, electroconvulsive therapy). Additional research is needed to further elucidate psychosocial and
biological factors that affect risk and course of LLD. In addition, research to identify psychobiological factors predicting
differential treatment response to various interventions will be essential to the development of more individualized
and effective approaches to the prevention and treatment of LLD.
Depression vs. resilience in late life
Late-life depression (LLD) is a common and debilitating
condition, with less frequent remission and more frequent
recurrence following first-line antidepressant treatment
compared to depression experienced earlier in life1–7.
Factors contributing to LLD are multifaceted, including
biological (e.g., genetic), psychological (e.g., personality),
and social influences (e.g., social support). With the world
population rapidly aging, it is increasingly important to
identify factors that increase resilience to the development
and maintenance of LLD.
Psychological resilience has been broadly defined as “the
capacity to maintain, or regain, psychological well-being
in the face of challenge”8. Resilience is a complex con-
struct that can be conceptualized as an attribute (a trait)
that is possessed to varying degrees by different
individuals, a dynamic process (a state) with bidirectional
relations to developmental and environmental factors,
and as an outcome in the face of stress and adversity9.
Depending on the theoretical perspective, population, and
risk factor in question, resilient outcomes may be oper-
ationalized as either the presence of a positive outcome
(e.g., life satisfaction) or the absence of a negative one
(e.g., lack of psychopathology)10. We conceptualize psy-
chological resilience as a multidimensional, dynamic
capacity influenced by the interaction of internal factors
(e.g., cognitive capacity, personality, physical health) and
external resources (e.g., social status, financial stability)11.
In the context of major depressive disorder (MDD), psy-
chological resilience refers to the net effects of a variety of
psychosocial and biological variables that decrease risk of
onset or relapse, decrease illness severity, or increase
probability or speed of recovery. The current review
describes resilience and vulnerability factors related to
LLD. We summarize psychosocial resilience factors that
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are universal across age groups as well as those unique to
aging. We also present results of research investigating
the neurobiological, genetic, and immunological bio-
markers of resilience.
Psychological resilience factors
Multiple psychological resilience factors reduce an
individual’s risk for depression across the lifespan12.
Enduring individual characteristics such as temperament,
attachment style, and personality each prospectively pre-
dict risk for depression. In addition, multiple psycholo-
gical processes are proposed to mediate this effect,
including beliefs and coping behavior. Psychosocial and
biological correlates of LLD are presented in Table 1. A
proposed model of how biopsychosocial factors influence
risk for LLD and illness course is presented in Fig. 1.
Temperament
Temperament is a basic inherited style, the structure of
which has been inferred largely from genetic studies.
Meta-analytic data indicate that within the temperament
dimensions, harm avoidance (i.e., “behavioral inhibition”)
is associated with greater MDD risk and decreased
treatment responsivity13. Research on individuals with
age-related illness suggests that harm avoidance is simi-
larly predictive of MDD in late life14,15. In contrast, meta-
analytic data indicate that positive emotionality (e.g.,
positive affect, extraversion, and behavioral activation)
decreases risk for depression16. Related longitudinal
research suggests that the capacity to experience positive
emotions such as gratitude, interest, and love is one
mechanism by which resilient individuals are buffered
against risk for depression following trauma17.
Attachment
Because early life attachment is thought to shape sub-
sequent relationships, attachment theory18–20 offers an
important framework for understanding the etiology and
development of depression across the lifespan21. Insecure
attachment is a risk factor for depression onset22, illness
severity, and relapse23. Research suggests that increased
emotional awareness24 and coping self-efficacy25,26 may
be two mechanisms by which secure attachment decrea-
ses stress reactivity. Longitudinal studies27 as well as
studies of children raised in orphanages28 indicate that
disorganized attachment during infancy predicts greater
amygdala volume—a hypothesized biomarker of difficulty
with emotion regulation28. Although attachment style
remains moderately stable throughout life, stressful life
events have potential to decrease secure attachment29,
while high relationship satisfaction and emotional open-
ness may increase secure attachment29. Research indicates
that insecure attachment continues to increase risk for
depression in late life30,31.
Table 1 Biopsychosocial correlates of late-life depression (LLD)
Psychosocial factors Resilience correlates LLD correlates
Temperament Positive emotionality Behavioral inhibition
Attachment Secure attachment Insecure attachment
Personality Extroversion, conscientiousness, grit Neuroticism
Beliefs Self-esteem, self-efficacy, mastery, growth mindset, sense of
purpose
Depression-related stigma, negative attitudes about
aging
Coping Active coping, accommodative coping, religious/spiritual practice Passive coping
Social factors Social support, formal volunteering Trauma, chronic stress, more social role "absences",
loneliness
Lifestyle factors Physical exercise, healthy diet Sedentary lifestyle, nutritional deficiencies, substance
abuse
Biological factors Resilience correlates LLD correlates
Genetics Val/Val allele, higher expression of mineralocorticoid
receptors
Val/Met allele, APOE-4e, SLC6A4, female sex
Neurophysiological Higher methylation of BDNF, higher neuropeptide Y,
efficient monoamine transmission
Neurodegeneration, white matter hyperintensities/vascular deficiencies,
shortened telomeres, lower heart rate variability, hippocampal atrophy
Steroid hormones Higher dehydroepiandrosterone (DHEA), moderate
availability of estrogens
Lower DHEA, low or very high availability of estrogens
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Personality
Multiple personality factors increase risk for MDD. A
recent meta-analysis controlling for baseline depressive
symptoms found that low extraversion, high neuroticism,
and low conscientiousness predicted depressive symp-
toms 5 years later32. Research on stroke survivors14,
individuals with Parkinson’s Disease33, and nonclinical
older adult samples34 has found similar associations,
suggesting that these effects are also observed in late life.
Another personality characteristic associated with resi-
lience is grit, defined as “perseverance and passion for
long-term goals” in the face of setbacks35. A recent study
of 337 adults with LLD found that grit was associated with
decreased severity of depression, apathy, and anxiety36.
Beliefs and coping behavior
Cognitive behavioral theory posits that an individual’s
beliefs about themselves, others, and the environment
influence coping behavior and subsequent psychosocial
adjustment37,38. For example, two recent meta-analyses
found that low self-esteem (i.e., a negative evaluation of
one’s self-worth) prospectively increased risk for depres-
sion39,40. Similarly, an individual’s self-efficacy for coping
with a given stressor impacts the coping strategy they
select and how long they persist in their efforts41. Coping
can be broadly divided into two domains: active (efforts to
directly “solve” the source of stress) and accommodative
(efforts to accept or adapt to the source of stress)42.
Research indicates that the ability to flexibly apply active
vs. accommodative strategies—i.e., using active approaches
for controllable stressors and accommodative approaches
for uncontrollable stressors—results in more favorable
mental health outcomes43–49. A recent study of 337 adults
with LLD found that both active coping self-efficacy and
accommodative coping self-efficacy were associated with
decreased depressive symptoms, apathy, and anxiety36. In
addition, greater baseline accommodative coping self-
efficacy predicted antidepressant treatment responsivity50.
In general, individuals with high self-efficacy for managing
stress through adaptive approaches such as physical
exercise, social support, and self-care are more likely to
engage in these strategies and less likely to develop pro-
longed symptoms of depression. In contrast, low coping
self-efficacy is associated with passive coping51, avoidance,
lower treatment adherence52,53, substance use54, and other
maladaptive coping strategies55 that may serve to increase
risk or course of depression.
An internal locus of control (i.e., “mastery”)56 is the
general belief in one’s ability to influence outcomes57.
Because this belief increases self-efficacy for coping with a
range of stressors, mastery can be conceptualized as
another resilience factor. Similarly, evidence suggests that
a “growth mindset”—the belief that one’s abilities can be
enhanced through effort—increases resilience by
increasing grit58. Finally, a strong sense of meaning/pur-
pose in life increases resilience to depression across the
lifespan59. A study of 1475 older Australian adults found
that higher sense of purpose was associated with less
disability, higher neurocognitive performance, and
decreased depressive symptoms, and predicted increased
survival in late life59. By contrast, depressed older adults
with symptoms of apathy generally have poorer clinical
outcomes60, quality of life (QOL)61,62, treatment
response63,64, cognitive impairment61, and disability62,
possibly resulting from decreased engagement in social-
and health-related behaviors62. Other studies have inves-
tigated the effect of meaning/purpose on risk for
depression among those at high risk due to exposure to
acute or chronic stress. A longitudinal study of bereaved
adults showed that two construals of meaning—making
sense of the loss and finding benefit in the experience—
both independently predicted decreased depressive
symptoms65. Other studies conducted with cancer survi-
vors66 and individuals with terminal illness67 also report
Fig. 1 Biopsychosocial factors influencing risk for LLD onset and
course. 1 Target of positive-psychology interventions and
psychotherapy. 2 Target of mindfulness-based interventions. 3 Target
of movement-based interventions. 4 Target of pharmacotherapy and
electroconvulsive therapy. 5Target of heart rate variability biofeedback
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associations between meaning and decreased depressive
symptoms. The results of one study suggest that increases
in perceived meaning and benefit finding may be one way
by which cognitive behavioral therapy helps prevent
depression among cancer patients68.
A final category of beliefs that increases risk for poor
outcomes in depression is mental illness stigma69. A
recent meta-analysis found strong associations between
internalized mental illness stigma and poorer psycholo-
gical resources (hope, self-esteem, empowerment), lower
treatment adherence, and greater mental illness symptom
severity70. In a study of adults with LLD, higher baseline
depression-related stigma predicted worse treatment
response, after controlling for baseline depression sever-
ity70,71. However, results of a longitudinal study of adults
with LLD suggest that mastery may moderate this effect72.
In that sample, anticipated stigma only predicted
increased depressive symptoms among those with low
mastery72. Mastery may counteract the negative impact of
anticipated stigma on mental health by increasing older
adults’ confidence in their ability to cope with stressors
such as interpersonal rejection.
Religion and spirituality
Religion and spirituality have been shown to pro-
spectively reduce risk for depression73. Whether such
effects are attributable to religious beliefs, behavior, or
social support remains a matter of debate. One investi-
gation of this question involved a study of over 1000 adult
Detroit residents74. In that study, religious attendance
(e.g., church, temple, synagogue) was associated with
greater psychological well-being and less emotional dis-
tress; frequency of prayer was associated with lower well-
being and more distress; and belief in eternal life was
associated with greater well-being but unrelated to dis-
tress. Religious attendance was associated with lower
distress even after controlling for sociodemographic
variables (e.g., age, sex, education), stressors (e.g., health
problems, financial problems), social resources (family
contact, support, and negative interaction), and psycho-
logical resources (self-esteem and personal mastery). By
contrast, a study of almost 3000 older Taiwanese adults
found that religious attendance no longer predicted
decreased depressive symptoms after controlling for
health behaviors, social networks, and supports75. Con-
sistent with the results of the Detroit study, religious
beliefs and depressive symptoms were unrelated. Finally, a
study of almost 8000 US older adults found that frequent
attendance of religious services predicted decreased
depression onset and frequent private prayer predicted
increased depression remission 2 years later. Results of
these studies indicate that religious coping behaviors may
be more strongly protective against depression than reli-
gious beliefs.
Psychological factors specific to late life
The types of stressors encountered by older adults are
qualitatively different than those faced by younger age
groups. Late-life stressors include voluntary or forced
retirement, chronic illness, cognitive decline, caregiving,
financial stress, loss of independence, and bereavement. If
these types of stressors are less controllable than those
encountered by younger age groups, this could make
accommodative coping especially essential in geriatric
populations76. Indeed, older adults appear to engage in
more accommodative coping77 and less instrumental
action coping76 compared to younger adults. Wrosch and
colleagues propose a developmental theory in which age-
adapted selection of coping strategies relates to optimal
well-being49. Consistent with this theory, active coping
(i.e., “persistence”) was significantly associated with well-
being in young adulthood and midlife, but not late life49.
Among older adults, accommodative coping was more
strongly associated with psychological well-being than
was persistence. Another study of LLD found that
accommodative coping self-efficacy was uniquely pre-
dictive of subsequent remission50.
Attitudes and stereotypes
One category of beliefs especially relevant to resilience
in late life includes attitudes about aging itself. Studies in
which negative stereotypes about aging are experimentally
activated have found that both implicit/subconscious and
explicit/conscious stereotypes negatively impact perfor-
mance in older people attempting physical and cognitive
tasks78,79. Other studies employing a cross-cultural
approach have found larger age differences in cognitive
performance in cultures with more negative
stereotypes80,81.
Social role and identity changes
Traditional perspectives have assumed that major life
changes inherently stressful82. However, research suggests
that role transitions such as retirement exert a wide range
of possible mental health effects83–85, including increasing
well-being when the change represents an escape from a
chronically stressful role situation86. A large Canadian
survey found that retiring from a low-stress job increased
depressive symptoms compared to not retiring, whereas
retiring from a high-stress job resulted in an effect twice
as large in the opposite direction86.
Several studies have found that a greater number of
“absences” in major social role-identities (marital, par-
ental, and employment) is associated with poor late-life
psychological adjustment87–89. Cumulating evidence
indicates that formal volunteering may buffer against this
effect by increasing social engagement, life satisfaction,
self-worth, personal growth, and sense of purpose/
meaning87,90–93. For example, a US study of almost 400
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older adults found that a greater number of major role-
identity absences was associated with more negative
affect, less positive affect, and less purpose in life87. For-
mal volunteering was associated with positive affect, and
volunteering positively moderated the relationship
between role-identity absences and purpose in life87.
Other studies have found that older adults typically
experience greater increases in life satisfaction with
volunteering compared to younger adults91 and that
adoption of a volunteer role may offset the negative
impact of spousal bereavement on subsequent depressive
symptoms94.
Social resilience factors
Systematic reviews suggest that both perceived social
support and objective social network size protect against
depression in the general population95 as well as in older
adults specifically96. Research investigating the mechan-
isms by which social networks enhance psychological
resilience indicates that both emotional support and
tangible (“instrumental”) support are important con-
tributors82. Research has also begun to distinguish
between the effects of objective vs. perceived social iso-
lation (i.e., loneliness)97. One study of over 1300 older
Irish adults concluded that these constructs were distinct
and that each independently predicted depressive symp-
toms98. An even larger US study of 20,000 adults found
that loneliness was correlated with a host of other risk
factors—less physical exercise, lower sleep quality, lower
social engagement, and poorer physical health99. Each of
these factors likely interact to predict susceptibility to
MDD. A cross-cultural review of additional social resi-
lience factors identified being married or cohabiting, male,
and having a higher family income each as associated with
reduced risk of depression in the US and Japan100.
However, a 3-year longitudinal study of American adults
aged 50–67 found that loneliness uniquely predicted
depressive symptoms after controlling for demographic
and psychosocial covariates such as marital status, per-
ceived stress, and social support101.
Social factors specific to late life
Adults tend to maintain fewer peripheral social partners
as they age102. It is hypothesized that an increasing
awareness of time as limited influences older adults to
prefer smaller and more emotionally satisfying social
networks103. Despite changes in social network structure
over time, the average degree of loneliness appears fairly
constant from middle- to late-life104. In a sample of over
1600 older adults participating in the Health and Retire-
ment Study, 43% reported feeling lonely105. Similarly to
findings with younger and middle-ages adults, loneliness
increases risk for depression in late life. For example, a
study of elderly Finish adults found that loneliness
predicted long-term trajectories of depression106. Addi-
tional social factors known to increase risk for LLD
include bereavement, sleep disturbance, disability, prior
depression, and female gender107. A meta-analysis of
gender differences in LLD suggests that some of these
effects are attenuated once sex differences in prevalence
of widowhood, health, and socioeconomic status are
accounted for108. Depression is also more common in
older adults living in institutions compared to those living
at home109,110.
Cognitive factors affecting resilience in LLD
LLD is associated with risk of cognitive decline111,112,
mild cognitive impairment (MCI)113,114, and demen-
tia111,115,116. One possible explanation for this association
is that LLD and cognitive decline are manifestations of the
same underlying neuropathology. Indeed, both LLD and
dementia are associated with reduced brain volume117,
increased hippocampal atrophy118, increased white matter
microstructural changes119, and altered structural and
functional connectivity63. Research suggests that chronic
stress-associated stimulation of the hypothalamic pitui-
tary adrenal (HPA) axis and associated over-secretion of
the stress hormone cortisol contribute to neurodegen-
eration120,121 that may increase risk for both LLD and
cognitive decline. In addition, depressive symptoms may
contribute to cognitive decline. Evidence supporting this
hypothesis comes from a longitudinal study of 1764 older
adults without cognitive impairment at baseline122. In that
study, depressive symptoms predicted cognitive decline
independent of the neuropathologic hallmarks of
dementia. Other research indicates that psychological
resilience may be neuroprotective. A recent study found
significant associations between self-reported resilience
and language performance among 288 adults with LLD123.
In addition, the resilience factor grit was associated with
greater structural integrity of the genu of the corpus
callosum and cingulum, pathways implicated in cognitive
and emotion regulation (N= 70)124.
The term cognitive reserve has been used to explain
differences in susceptibility to cognitive decline resulting
from brain aging, pathology, or insult125. Individual dif-
ferences in cognitive reserve are determined by such
factors as early-life general cognitive ability/intelligence,
education level, occupation complexity, physical exercise,
social engagement, and ongoing cognitive engagement126.
These environmental and social factors are believed to
enhance neural networks that promote neuroplasticity.
Cognitive reserve may also serve as a psychological resi-
lience factor. A recent systematic review representing data
from over 37,000 older adults found that cognitive reserve
decreased the association between cognitive impairment
and depressed mood127. Of course, factors associated with
cognitive reserve such as education are also associated
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with engagement in health-promoting behaviors that may
further protect the individual against both depression and
cognitive decline128.
Other research has attempted to identify cognitive fac-
tors that predict treatment response in LLD. One recent
study found that impairment in response inhibition (a
fundamental executive function) predicted poor anti-
depressant response in LLD129. Other studies have simi-
larly found that baseline impairments in episodic working
memory, processing speed, executive function, as well as
severity of baseline white matter hyperintensities (WMH)
predict decreased LLD improvement with antidepressant
treatment130.
Psychobiological resilience factors
The stress response and LLD
Recent research has begun to investigate the biological
mechanisms by which chronic stress increases risk for
depression131–135. In a psychobiological framework, resi-
lience can be defined as the adaptive maintenance of
homeostasis in the face of stress or adversity136. Building
psychobiological resilience begins with prenatal and early-
life development134. Experimental studies in animals136 as
well as observational studies in humans137,138 point to an
inverted U-shape between early life challenges and adult
stress reactivity, with moderate challenges in early life
predicting optimal mental health in adulthood. Animal
studies indicate that this so-called “early-life stress
inoculation” decreases subsequent cortisol secretion and
increases subsequent exploration of novel situations,
cognitive control, and ventromedial prefrontal cortical
volumes138. It is hypothesized that prefrontal myelination
and cortical expansion induced by successful early-life
coping lead to enduring adaptive cognitive and emotional
changes138. By contrast, high levels of early-life adversity
adversely impact attachment, personality, core beliefs, and
coping tendencies, ultimately leading to enduring changes
in endocrine, autonomic, and immunological pro-
cesses139, and increasing vulnerability to depression132,140.
Genetic factors also contribute. One study found that a
functional polymorphism in the promoter region of the
serotonin transporter (5-HTT) gene moderated the
influence of both childhood stress and later stressful life
events on risk for depression141.
One prominent hypothesis for how chronic stress
increases risk for depression is through sustained activa-
tion and ultimate dysregulation of the HPA axis142. Of the
stress hormones, cortisol has received the most research
attention due to its widespread regulatory influence143.
Research suggests that although uncontrollable stress
initially amplifies cortisol secretion, sustained elevated
levels of cortisol eventually suppress output of
corticotropin-releasing hormone (CRH) and adreno-
corticotropin hormone143, resulting in below-normal
cortisol levels in chronically stressed populations144.
This ultimate blunting of HPA axis responsivity is pro-
posed to underlie the withdrawal and disengagement
behaviors that often accompany chronic uncontrollable
stress144–146. Disrupted HPA axis activity as evidenced by
failure to suppress cortisol in the dexamethasone test
predicts increased suicide risk in both MDD147 and
LLD148, and recent research indicates that low miner-
alocorticoid receptor availability also increases risk for
depression149.
In addition to altering cortisol secretion, sustained
activation of the HPA axis results in deficient monoamine
transmission, disruption of neurotrophic processes (e.g.,
the neuroprotective brain-derived neurotrophic factor
(BDNF)), oxidative stress, widespread inflammatory pro-
cesses, and neurodegeneration136,142. Dysfunction in ser-
otonergic and dopaminergic transmission contribute to
the common mood and cognitive symptoms observed in
depression142,150. Once in motion, this stress-related
biological cascade can be exacerbated by environmental
factors (e.g., social isolation) or maladaptive coping
behaviors (sedentary lifestyle, substance abuse)134.
Neuropeptides
Multiple neuropeptides are known to modulate emo-
tional processing. Neuropeptide Y (NPY) has been pro-
posed as an endogenous mediator of resilience to stress-
related psychiatric illness, including depression151. NPY
plays a key role in the maintenance of homeostasis and
has been implicated in diverse motivational, perceptual,
and affective processes including circadian rhythm, anxi-
ety, appetite, alcohol consumption, and pain percep-
tion152. NPY receptors are densely expressed in brain
regions relevant to mood disorders including the cortex,
hippocampus, and amygdala. Low NPY levels have been
reported in MDD compared to healthy controls153, and
genetic variation associated with low NPY expression
increases risk for MDD153,154. Results of one study suggest
that this effect may be mediated by increased neuronal
response to affective stimuli in the medial prefrontal and
anterior cingulate cortices among individuals with low-
expression NPY genotypes154.
Endocrine changes in aging and depression
One potential vulnerability for depression specific to
older adults is age-associated decline in reproductive
hormones. Perimenopause increases risk for both recur-
rent and new-onset depression155. Loss of normal estra-
diol (the primary circulating estrogen) cycling is proposed
to account for this increased vulnerability via effects on
neurotransmitter and mood regulatory systems155.
Estrogen receptor polymorphisms have been associated
with heightened depression risk in older women156,157,
and maintenance of normal estrogen levels is important
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for several brain regions vulnerable to age-related chan-
ges158 (e.g., the prefrontal cortex (PFC) and hippo-
campus)134,159,160. Similarly, age-related reduction in
dehydroepiandrosterone (DHEA) has been linked to
depression, cognitive decline, reduced immune function,
and decreased physical health161,162. Individuals with LLD
demonstrate lower DHEA levels compared to non-
depressed older adults, and DHEA levels increase with
remission163.
Cardiovascular markers
There is strong evidence for a bi-directional association
between depression and cardiovascular disease. Pro-
spective studies indicate that individuals with depression
are at nearly twice the risk of developing cardiovascular
disease and have nearly a three times higher mortality rate
following a cardiac event164,165. Conversely, cardiovas-
cular disease prospectively predicts depression166,167.
Although unhealthy behaviors (e.g., unhealthy diet, lack of
physical activity) undoubtedly contribute to this effect,
lifestyle factors do not fully explain the relation between
heart health and depression168.
Autonomic nervous system (ANS) dysregulation is one
biological mechanism that may explain the link between
cardiovascular risk and depression169. Heart rate varia-
bility (HRV) is a surrogate index of resting cardiac vagal
outflow that represents the ability of the ANS to adapt to
a changing psychological, social and physical environ-
ment170. Higher HRV is thought to reflect greater self-
regulatory capacity (i.e., regulation of behavioral, cogni-
tive, and emotional processes), and meta-analytic data
suggest that this effect is larger for older compared to
younger adults171. Recent research suggests that high
HRV may serve as a biomarker of resilience to the
development of stress-related disorders172 including
depression168,173. However, age-related differences have
been reported in the frequency of the HRV most pre-
dictive of depression. Whereas low high-frequency (HF)-
HRV (reflecting parasympathetic activity174) is associated
with depression among children173, adolescents173, and
young adults175, only low low-frequency (LF)-HRV
(reflecting both sympathetic and parasympathetic activity)
appears associated with depression among older adults168.
Decreased parasympathetic activity with age appears to
result in decreased HRV in the general (primarily non-
depressed) older adult population176,177, which may par-
tially account for this finding.
Inflammation in aging and depression
Cumulating evidence indicates immune and metabolic
dysregulation among individuals with depression178.
Immunometabolic dysregulation is associated with more
severe and chronic depressive symptoms179–181 as well as
decreased response to antidepressant treatment182–184,
and may explain the increased prevalence of cardiovas-
cular disease and diabetes in MDD185. While studies of
younger adults typically show upregulation of metabolic
processes in depression, studies of LLD report both
upregulation and downregulation of these processes186–
189. Both younger190 and older191 adults with depression
show increased levels of inflammatory cytokines, secreted
proteins that interact with virtually every depression-
relevant neurophysiological domain (e.g., neuro-
transmitter metabolism, neuroendocrine function, and
neural plasticity). Additional evidence for the role of
inflammation in depression comes from studies indicating
that (1) pro-inflammatory factors precede depressive
symptom onset191, (2) antidepressant treatments reduce
pro-inflammatory factors192, and (3) anti-cytokine therapy
decreases depressive symptoms in placebo-controlled
trials193. Experimental data indicate that acute psychoso-
cial stress (e.g., public speaking, mental arithmetic) sti-
mulates inflammatory signaling molecules194, and these
responses are exaggerated in patients with depression190.
Both childhood maltreatment195 and chronic stress in
adulthood196–198 are associated with increased inflam-
mation. Thus, inflammation may be one pathway by
which these psychosocial factors increase risk for
depression.
Genetic factors in aging and depression
At least three genes have been associated with increased
risk for LLD: the methionine (Met) allele of the neuro-
trophic factor BDNF199, APOE-e4 (involved in myelin
repair and Aβ metabolism), and SLC6A4 (the short allele
of the serotonin transporter 5-HTTLPR)200. BDNF is a
protein that stimulates neurogenesis and is important for
long-term memory. The Met variation of the BDNF gene
is associated with decreased BDNF secretion201, poorer
memory performance202, and increased risk for a range of
neuropsychiatric disorders203. Interestingly, a meta-
analysis found that the Met allele predicted MDD
among men but not women204. Another meta-analysis
found that the Met allele significantly moderated the
effect of stressful life events on MDD risk, suggesting that
Met carriers are more genetically sensitive to adverse life
experiences205. A recent longitudinal study conducted
with over 1000 older adults found that epigenetic reg-
ulation of the BDNF gene was associated with depres-
sion206. Another study of individuals with LLD found that
the Met allele predicted poorer response to paroxetine,
and that this effect was moderated by the cyclic AMP
responsive element binding protein 1 (CREB1)207.
Neuroimaging biomarkers of aging and depression
Emerging research evidence suggests that MDD is
associated with reduced structural and functional plasti-
city208,209. Brain structures important for learning and
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applying adaptive coping strategies (e.g., the hippocampus
and PFC) show atrophy in MDD210–214, possibly resulting
from depression-related hypercortisolemia215,216. Similar
abnormalities (i.e., decreased limbic structure volumes
and reduced PFC activity) have been found in LLD215,217–
219. However, research suggests that at least with regard to
decreased hippocampal volumes220, these effects may be
more pronounced for individuals with earlier depression
onset. Narayan and colleagues propose that prior
depressive episodes, aging, stress, hypercortisolemia, and
reduced BDNF levels cause focal atrophy and may
decrease the threshold for mood disorders in late life221.
Neuroimaging biomarkers of emotion regulation, coping,
and grit
Substantial neuroimaging research has investigated the
neural networks implicated in emotion regulation and
coping with stress. Despite the neural structures hypo-
thesized to underlie emotion regulation being vulnerable
to age-related decline222, behavioral evidence suggests
that older adults have better emotion regulation capacity
compared to younger adults223. Functional magnetic
neuroimaging (fMRI) studies have documented increased
activation of the PFC and amygdala224,225 in older vs.
younger adults during tasks requiring emotion regulation
tasks, possibly reflecting compensation for less efficient
cognitive processing224.
Other studies have attempted to identify the neural
correlates of adaptive coping with stress. For example, a
study of 102 heathy adults found that the functional
connectivity of regions associated with the default mode
and anterior salience networks was associated with pro-
pensity to adopt various coping strategies (e.g., problem-
focused, avoidant, social support seeking)226. Others have
investigated individual differences in brain structure that
relate to personality characteristics associated with resi-
lience to depression. As reported above, grit has been
associated with greater structural integrity of the genu of
the corpus callosum and cingulum in LLD—pathways
implicated in cognitive and emotion regulation36,124.
Finally, several studies have documented neuroimaging
correlates of self-reported resilience. Among healthy
adults, self-reported resilience was correlated with
decreased electroencephalogram (EEG) responsivity to
adverse images227. In LLD, correlates included low
amygdala blood perfusion at rest and greater functional
connectivity between the amygdala and the ventral default
mode network228.
Structural brain changes and cerebrovascular disease in
aging and depression
WMH are another related biological mechanism that
may explain the link between cardio- and cerebrovascular
disease and depression in late life. LLD is consistently
associated with greater WMH severity229,230, and indivi-
duals with late onset exhibit greater WMH severity220,231–
234 and greater cognitive impairment234–236 compared to
those with first onset earlier in life. Depressed older adults
who present with WMH are said to have “vascular
depression”237, a subtype of depression characterized by
cognitive deficits, psychomotor retardation, lack of
insight, and disability disproportional to depression
severity238. Such vascular abnormalities are linked to
greater depressive symptom severity and poorer treat-
ment response239,240. WMH are also strongly and inde-
pendently associated with symptoms of apathy241–245.
Psychobiological factors associated with early- vs. late-
onset LLD
Several studies have investigated the clinical correlates
of early- vs. late-onset LLD. One study investigated illness
severity and symptoms, cognitive function, antecedent life
events, physical health, genetic factors, and vascular
health as a function of age of onset in 57 adults with
LLD246. They found that early onset was associated with
increased symptoms of anxiety and greater heritability.
Several studies of LLD have found that early-onset
recurrent illness predicts slower treatment responses
and greater relapse compared to late onset247. This may
be due to a greater number of depressive episodes, which
is associated with the depletion of neural248, inter-
personal249,250 and psychosocial resources249,250. These
results are seemingly in contrast to the results of studies
identifying characteristics associated with late onset (i.e.,
increased subcortical hyperintensities234, decreased cog-
nitive performance234), which have also been associated
with inadequate treatment response239,240.
Resilience-enhancing interventions
Resilience-enhancing interventions can be implemented
either preventatively to reduce susceptibility to MDD or
as a treatment following MDD onset. Prevention strate-
gies promote well-being even in the absence of current
psychopathology, and can be applied both to healthy
individuals or to those at high risk (i.e., those with chronic
stress, trauma, or history of prior depressive episodes).
The field of positive psychology251 defines well-being as
not the absence of a mental disorder, but rather the
presence of well-being, and advocates for the widespread
application of such techniques regardless of the presence
or absence of psychopathology.
Positive psychology interventions
Positive psychology interventions (PPIs) are “treatment
methods or intentional activities that aim to cultivate
positive feelings, behaviors, or cognitions”252(p. 468). PPIs
typically target hedonic well-being (e.g., positive affect, life
satisfaction, happiness)253, eudaimonic well-being (e.g.,
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self-acceptance, positive relations, autonomy, purpose in
life)254,255, or both, and are typically amenable to self-
administration. Such approaches vary widely in intensity,
ranging from a several minute-long daily gratitude journal
to more in-depth journal exercises, meditations, and
intentional social behaviors. Research suggests that PPIs
not only increase well-being, but also improve the indi-
vidual’s capacity to “bounce back” from adversity. A
recent meta-analysis of PPIs including data from over four
thousand adults indicated a highly significant, moderate
effect of PPIs on both well-being (r= 0.29) and depressive
symptoms (r= 0.31)252. PPIs included expressing grati-
tude256,257, reflecting upon one’s ideal future self257–260,
identifying one’s strengths256, practicing mindfulness261,
and practicing compassion/ acts of kindness262–265.
Interventions delivered individually were most effective,
followed by those administered in a group, then by self-
administered PPIs. The efficacy of PPIs increased linearly
with participant age, and depressed individuals benefitted
more than non-depressed individuals252. Another PPI
shown to improve mood in individuals at risk for
depression due to trauma exposure is “benefit finding”, or
the intentional identification of positive ways in which
their lives have changed as a result of a traumatic
event266,267. Bower and colleagues268 propose an inte-
grative conceptual model in which benefit finding pro-
motes the development of interpersonal resources (e.g.,
adaptive coping strategies including cognitive re-apprai-
sal; increased self-efficacy for coping with stress; more
salient sense of one’s values/purpose) and intrapersonal
resources (e.g., enhancement of social relationships) that
facilitate more adaptive responses to future stressors.
More broadly, PPIs that increase one’s feeling of con-
nection to others (e.g., expressive gratitude, practicing
compassion may not only directly improve mood but also
exert beneficial neuroendocrine, cardiovascular, and
immune systems changes269. PPIs aimed at enhancing
meaning/purpose (e.g., reflecting upon one’s ideal future
self; identifying strengths) are also thought to improve
markers of immune functioning270. In addition, it is
possible that the positive psychological changes elicited
through PPIs have their own mechanistic pathways dis-
tinct from those associated with distress—e.g., para-
sympathetic nervous system activity, growth factors, and
other neuroendocrine factors such as oxytocin271.
Although PPIs are not recommended as a stand-alone
treatment for moderate-to-severe MDD, research sug-
gests that PPIs may be useful for the prevention or
adjunct treatment of depression252.
Meditation
Meditation refers to a category of mind–body techni-
ques most commonly involving the directed focus of
attention. One form of Buddhist meditation techniques
that has been adapted to a variety of secular settings in the
West is mindfulness—intentional, non-judgmental,
present-focused awareness272. A recent meta-analysis
indicated that mindfulness-based interventions are sig-
nificantly more effective than psychoeducation, suppor-
tive psychotherapy, relaxation training, and guided
imagery for improving a range of mental and physical
health symptoms, with the largest effects demonstrated
for mental health symptoms including depression273. A
recent review of randomized controlled trials (RCTs) of
mindfulness-based interventions for older adults con-
cluded that Mindfulness-Based Stress Reduction (MBSR)
is effective for improving symptoms of depression, anxi-
ety, positive affect, insomnia, chronic pain, memory, and
executive functioning in late life274. Other research con-
ducted with adults with MDD has found that MBSR is
effective for preventing relapse in those with a history of
three or more depressive episodes275. A recent systematic
review evaluating the biopsychological mechanisms by
which mindfulness practice affects clinical outcomes
concluded that decreases in cognitive reactivity, emo-
tional reactivity, rumination, and worry may mediate the
effect of mindfulness interventions on mental health276.
Mindfulness practice appears to alter both brain structure
and function, most notably in areas related to attentional
control, self-awareness, and emotion regulation277–279. In
addition, mindfulness interventions may protect against
age-related decreases in gray matter volume280, attention
performance281, and cellular aging282.
Other forms of yogic-style meditation include those
involving repetition of sounds (mantras) or hand positions
(mudras). A recent study found that Kirtan Kriya (which
combines mantras and mudras) was more effective for
improving mental health and cognitive functioning in
dementia caregivers compared to passive listening to
relaxing music283. Further, Kirtan Kriya reversed the
pattern of increased pro-inflammatory cytokine and
decreased innate antiviral response gene transcription
observed in chronically stressed individuals. Results of
this study indicate inflammatory and antiviral transcrip-
tion pathways as one mechanism by which meditation
may increase resilience in older adults284. Another ran-
domized study of mantra meditation for elderly women
with hypertension found that chanting significantly
reduced depression, anxiety, stress, blood pressure, and
cognitive impairment285. Studies investigating the neu-
rohemodynamic correlates of mantra meditation suggest
that deactivation of the limbic system may account for
observed decreases in physiological arousal and
improvements in well-being286.
Psychotherapy
Meta-analytic data suggest that psychotherapy is simi-
larly effective as pharmacological approaches in the
Laird et al. Translational Psychiatry            (2019) 9:88 Page 9 of 18    88 
treatment of LLD287,288, with a number needed to treat of
3 (ref. 288). A meta-analysis of RCTs comparing psy-
chotherapy for LLD to various control conditions found
the largest effects for cognitive behavior therapy (CBT; g
= 0.45), problem-solving therapy (g= 0.46), and life
review therapy (g= 0.59)287. A more recent review
focused on mindfulness-based CBT found such inter-
ventions to be similarly effective for improving late-life
depressive symptoms (g= 0.55)289. Results of another
meta-analysis suggest that music therapy significantly
augments the efficacy of standard treatments for LLD290.
Because alterations of the HPA axis and the ANS appear
to be involved in the development and maintenance of
depression, it is conceivable that these dysregulations may
interact with psychotherapeutic treatment to influence
outcomes. A meta-analysis that attempted to investigate
the effect of psychotherapy on HPA and ANS regulation
in adults with mixed mental health disorders concluded
that this effect could not be estimated due to the large
degree of heterogeneity of methodologies across
studies291.
Movement-based interventions
Physical exercise is effective for the treatment of MDD,
with effect sizes similar to those observed with pharma-
cological and psychological therapies292. A recent sys-
tematic review confirmed that physical activity
interventions are also effective in LLD293. In addition to
the documented effects on mood, physical activity is
associated with improved balance, greater strength, and
decreased disability. One mechanism by which exercise
interventions affect both physical and mental health may
be via reduction in inflammatory cytokine responses
resulting from hemodynamic hormonal changes during
physical activity294. Movement-based interventions that
also incorporate mindfulness are referred to as
mind–body therapies (MBTs). A recent review of the
efficacy of such interventions for late-life mood and
cognitive disorders concluded that MBTs such as yoga
and tai chi may outperform conventional physical exercise
with regard to effects on mood, QOL, and cognitive
functioning295. A review of the neural mechanisms of
movement-based vs. stationary meditation found that
these two approaches affect multiple common brain
regions including those involved in attention, memory,
awareness, and emotional processing296. Yoga appears to
reduce HPA axis activity in younger healthy adults297,298
as well as in sedentary community-dwelling older adults
without depression299. It is possible that restoration of
HPA axis dysregulation may be one mechanism by which
MBTs improve mood in older adults with depressive
symptoms283,300–302.
Pharmacotherapy
Second-generation antidepressant medications, includ-
ing selective serotonin reuptake inhibitors (SSRIs),
bupropion, mirtazapine, venlafaxine, and duloxetine are
the most commonly prescribed pharmacological treat-
ments for LLD. A recent meta-analysis of second-
generation antidepressants vs. placebo for treatment of
LLD found that response rates were modest (44% for
antidepressant vs. 35% for placebo)3. Response rates were
higher for 10–12-week trials (55%) compared to 6–8-
week trials (38%)3. However, results of another meta-
analysis comparing placebo-controlled vs. comparator
trials in LLD suggest that these effects may underestimate
those in clinical settings, when patient expectations of
improvement may be higher303. Discontinuation rates due
to adverse events associated with second-generation
antidepressant medication range from 8–27%, compared
to 1–11% for placebo3. The precise neurophysiological
mechanisms of antidepressant medications remain
unknown. However, meta-analytic data indicate normal-
ization of neural responses to positive and negative sti-
muli in limbic regions as well as increased self-regulatory
potential via changes in the dorsolateral PFC304.
Electroconvulsive therapy
Electroconvulsive therapy (ECT) is widely used for the
management of severe and refractory MDD305. As the
most effective biological treatment for major depression,
ECT is associated with remission rates of 51% (ref. 306)
and standardized effect sizes of 0.91 compared to sham
ECT307. Reviews indicate that ECT is especially effective
in older adult patients, with remission rates reaching
73–90% (refs. 308–312). In addition, psychotic and melan-
cholic features predict greater response312. Use of ECT for
LLD is safe, well-tolerated, and effective for improving
cognition and psychomotor symptoms313. Maintenance
ECT, with treatments spaced over weekly to monthly
intervals, is often used for relapse prevention314. Recom-
mendations for optimal administration of ECT for LLD
can be found elsewhere312. The results of one study
investigating the neurological effects of ECT suggest that
increases in frontal white matter fractional anisotropy
(FA) (typically reduced in LLD compared to age-matched
controls315) may account for ECT’s antidepressant
effect315. Another study found gray matter volume
increases in the right caudate nucleus with ECT treatment
for LLD, a change which correlated with improved psy-
chomotor function313.
HRV biofeedback
Small uncontrolled studies have shown some promise
for HRV biofeedback in the treatment of MDD316,317, and
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one RCT found that HRV biofeedback significantly
improved depressive symptoms in first-time cardiac sur-
gery patients compared to usual care318. It is thought that
strengthened homeostasis or effects on the vagal afferent
pathway to frontal cortical areas may account for this
effect319. However, no RCTs to date have examined the
efficacy of HRV biofeedback in LLD.
Directions for future research and public policy
During this critical time of accelerated global aging,
understanding factors that promote resilience vs. risk for
the development of LLD and related comorbidities is
more important than ever. Continued research in this area
is essential for informing practice and public policy to
promote successful aging, reduce disability, and mitigate
rising healthcare costs. One fruitful area for future
research is the investigation of individual characteristics
that moderate risk factors for LLD. For example, research
suggests that risk factors for depression may vary
according to generation110, gender, and cultural origin.
Variables such as self-esteem and self-efficacy are highly
culturally and contextually dependent, such that the effi-
cacy of interventions targeting these processes will likely
vary across cultures. Indeed, PPIs as a whole appear more
effective among members of individualist cultures320,
perhaps because the rationale for such approaches reso-
nates more strongly with individuals from cultures
endorsing the pursuit of individual happiness. It is pos-
sible that individuals from collectivist cultures may derive
greater benefit from prosocial and other-focused PPIs
(e.g., performing acts of kindness, writing a letter of gra-
titude), compared to self-focused PPIs (e.g., reflecting on
personal strengths)252.
Similarly, continued investigation of the biological fac-
tors that increase or mitigate risk for depression is of
paramount importance. Results of a recent meta-analysis
suggest that depressed individuals with higher baseline
cortisol levels are less responsive to psychological ther-
apy321. Because elevated cortisol has been linked to con-
centration and memory difficulties322, the authors
propose that difficulty engaging in learning processes may
reduce the efficacy of psychotherapy in this subset of
MDD patients. Additional research is needed to identify
other biomarkers of depression “subtypes” as well as
determine as well as the interventions most effective for
each. Continued work in this area is essential for the
development of more effective approaches to the treat-
ment of LLD.
Resilience-enhancing interventions can be applied not
only at the individual level, but also at the level of the
family, organization, or community. A recent systematic
review of family-oriented interventions found that dyadic
interventions such as ecosystems therapy, psychoeduca-
tion, family counseling, behavioral therapy, and CBT are
feasible and effective for the treatment of LLD323. In
addition, the results of two pilot studies suggest that
mindfulness training delivered jointly to older adult
patients and their caregivers is effective for reducing
depressive symptoms324–326.
Other research has identified potentially useful direc-
tions for organizations that wish to promote resilience in
their older adult volunteers. A recent study of almost 400
older adult volunteers identified adequate training,
ongoing support, and greater volunteer choice as pre-
dictors of larger volunteer mental health benefits327. This
effect was mediated by the volunteer’s belief that their
work had meaningfully contributed to the well-being of
others327.
Factors influencing risk for LLD can also be identified at
the community and public policy levels. Because lone-
liness affects nearly half of the Americans99 and inde-
pendently predicts severity and course of LLD328,
loneliness is a promising target for intervention. Of note, a
recent review of seven RCTs found that social robot
interventions may be effective for helping to alleviate
depressive symptoms in older adults when used during
group activities329. Programs to promote greater integra-
tion of older adults into their communities (e.g., by
facilitating the sharing of meals, joint physical activity,
support groups, or interactive volunteer work) are
recommended. Of course, factors such as a balanced diet,
physical activity, and sufficient sleep are also of para-
mount importance. As such, public policies that provide
food stamps and low-cost healthy food options, safe
opportunities for physical exercise, preventative medical
care, and financial assistance to those older adults in need
will reduce the economic, social, and individual QOL
burden of LLD.
Conclusion
With the global population rapidly aging and depres-
sion as the leading cause of disability worldwide, identi-
fication of factors that increase resilience to LLD is of
paramount public health importance. Risk for LLD
begins as early as embryonic development and is deter-
mined by complex interactions between biological and
psychological factors. Research has elucidated both trait-
like psychological factors that identify those at greatest
risk and psychosocial processes that may be fruitful tar-
gets for intervention. Psychobiological factors include
endocrine, genetic, inflammatory, neural, and cardiovas-
cular processes that bidirectionally interact to affect LLD
risk. Intervention research suggests that MBTs (including
yoga299,330,331, MBSR332, tai chi333,334, qigong302, and
meditation335,336) have potential for improving HPA axis
regulation299 and depressive symptoms in older adults
with depression283,300–302 as well as in non-depressed
older adults330–332,334–336.
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Additional research into the biophysiological mechan-
isms by which psychosocial processes affect risk for LLD
will identify novel targets for intervention. In addition,
continued research testing the efficacy of interventions
designed to enhance resilience to LLD is critically
important. Further work in this area has potential to
greatly increase QOL, reduce morbidity, and decrease
healthcare costs for aging adults.
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